ABT - Abbott Laboratories
75.54 0.00 (0.00%)
After hours: 5:09PM EST
| Previous Close | 75.00 |
| Open | 74.83 |
| Bid | 74.80 x 1800 |
| Ask | 77.25 x 1400 |
| Day's Range | 74.60 - 75.57 |
| 52 Week Range | 56.81 - 75.57 |
| Volume | 6,316,696 |
| Avg. Volume | 6,914,290 |
| Market Cap | 132.673B |
| Beta (3Y Monthly) | 0.87 |
| PE Ratio (TTM) | 56.84 |
| EPS (TTM) | 1.33 |
| Earnings Date | Apr 16, 2019 - Apr 22, 2019 |
| Forward Dividend & Yield | 1.28 (1.71%) |
| Ex-Dividend Date | 2019-01-14 |
| 1y Target Est | 80.08 |
Market Realist•12 hours agoBoston Scientific or Abbott: A Look at Expected EPS Growth
How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Earnings projections for fiscal 2019In its fourth-quarter earnings investor presentation, Boston Scientific (BSX) has guided for adjusted EPS of $1.53–$1.58 for
- Zacks•12 hours ago
CVS Health's (CVS) Q4 Earnings Top Estimates, Margins Up
CVS Health's (CVS) recently introduced Health Care Benefits segment following the Aetna acquisition holds immense promise.
- Zacks•13 hours ago
Intuitive Surgical Gets FDA Nod for Ion Endoluminal System
The regulatory go-ahead for the Ion platform is likely to provide Intuitive Surgical (ISRG) a competitive edge in the minimally-invasive-care space.
Market Realist•14 hours agoBoston Scientific or Abbott: Who Will Report More Revenue Growth?
How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Revenue guidance for fiscal 2019In its fourth-quarter earnings investor presentation, Boston Scientific (BSX) guided for YoY revenue growth of 7%–9%, YoY organic
- PR Newswire•14 hours ago
Abbott and Novo Nordisk Enter Partnership to Provide Integrated Digital Solution to People with Diabetes Using Insulin
ABBOTT PARK, Ill. and BAGSVÆRD, Denmark, Feb. 20, 2019 /PRNewswire/ -- Abbott (ABT) and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools compatible with the FreeStyle Libre system (FreeStyle LibreLinkii mobile app and LibreViewiii cloud-based system). The partnership reflects both companies′ commitment to make diabetes management easier by connecting key technologies such as continuous glucose monitoring (CGM) and connected insulin pens.
- Market Realist•15 hours ago
What Analysts Recommend for Boston Scientific and Abbott
How Boston Scientific and Abbott Laboratories Stack UpStock price movementsOn February 15, Boston Scientific (BSX) closed at $40.01, 0.23% higher than its previous closing price, 52.30% higher than its 52-week low of $26.27, and 0.79% below its
- PR Newswire•15 hours ago
Abbott Introduces the World's Most Sensitive Rapid Diagnostic Test, Determine™ HBsAg 2, to Accelerate Hepatitis B Care
ABBOTT PARK, Ill., Feb. 20, 2019 /PRNewswire/ -- Abbott (ABT) announced today it has received CE Mark for the world's most sensitive rapid diagnostic test for the detection of hepatitis B surface antigen, the Determine™ HBsAg 2 test for use with serum, plasma or whole blood.1,2,3 This highly sensitive, easy-to-use, rapid lateral flow test enables identification of those with the virus and facilitates linkage to care in every healthcare setting.
- TheStreet.com•yesterday
Trading Notes for Select Stocks
On a regular basis I make notes on all the stocks I've been trading. This allows me to stay focused on my overall thesis and to have a clear plan of action. I generally will have 50 or more names.
- Zacks•yesterday
Medtronic (MDT) Beats on Q3 Earnings, Gross Margin Down
Medtronic (MDT) demonstrates improved performances at CER based on growth in most of the business segments and all geographies.
- Zacks•2 days ago
Medtronic Posts Prelim PRODIGY Outcome on Opioid Overdose
The favorable PRODIGY study result by Medtronic (MDT) is undoubtedly a timely, strategic finding.
- Zacks•2 days ago
Here's Why Investors Should Buy Surmodics (SRDX) Stock Now
Surmodics' (SRDX) solid efforts to improve its research and development stature are likely to prove beneficial in the quarters ahead.
- Zacks•2 days ago
Align Technology Unveils iTero Element 5D Imaging System
Align Technology (ALGN) continues to expand work flow options of iTero scanners.
- Zacks•3 days ago
Cryolife (CRY) Earnings Miss, Revenues Top Estimates in Q4
Cryolife (CRY) revenues increase year over year across all geographies and major segments.
- Markit•3 days ago
See what the IHS Markit Score report has to say about Abbott Laboratories.
Abbott Laboratories NYSE:ABTView full report here! Summary * Perception of the company's creditworthiness is neutral * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ABT with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ABT. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ABT totaled $11.09 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NeutralThe current level displays a neutral indicator. ABT credit default swap spreads are within the middle of their range for the last three years.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•6 days ago
Here's Why You Must Buy Cardiovascular Systems' (CSII) Stock
Cardiovascular Systems (CSII) has been firing on all cylinders of late to expand its geographical presence. The company is progressing well with its objective to introduce OAS globally.
- Zacks•6 days ago
Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B
Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.
- Zacks•6 days ago
Quest Diagnostics (DGX) Q4 Earnings in Line, Margins Down
In recent times, Quest Diagnostics (DGX) is facing several reimbursement issues which have hurt revenues.
- Zacks•7 days ago
Baxter's Acute Therapies Profile Strong, Competition Rife
Expanding product portfolio and strong presence in the international markets are key positives for Baxter (BAX) at the moment.
- Zacks•7 days ago
Bio-Techne (TECH) Q2 Earnings Beat, Gross Margin Declines
Bio-Techne (TECH) sees increase in revenues across key segments.
Motley Fool•7 days agoQuidel Corp (QDEL) Q4 2018 Earnings Conference Call Transcript
QDEL earnings call for the period ending December 31, 2018.
- Zacks•9 days ago
STERIS (STE) Q3 Earnings In Line, Revenues Beat Estimates
STERIS (STE) continues to gain from strength in all business segments in Q3.
- Zacks•8 days ago
Boston Scientific Benefits From New Buyouts & Product Launch
Boston Scientific's (BSX) closure of Millipede acquisition and its buyout agreement with BTG plc are major developments for the company.
- Zacks•8 days ago
Here's Why Investors Should Retain AmerisourceBergen Stock
AmerisourceBergen (ABC) expects to witness solid growth at the Pharmaceutical Distribution segment in the long term.
- Zacks•8 days ago
Edwards Lifesciences to Buy CASMED to Boost Critical Care Arm
The CASMED buyout is expected to strengthen Edwards Lifesciences' (EW) position in smart monitoring technologies and boost top-line contributions from the Critical Care arm.
